首页> 美国卫生研究院文献>EBioMedicine >Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic Lesions
【2h】

Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic Lesions

机译:致癌性Kras诱导的液相内吞作用的增加取决于N-WASP是胰腺癌前病变形成的必需条件

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Fluid-phase endocytosis is a homeostatic process with an unknown role in tumor initiation. The driver mutation in pancreatic ductal adenocarcinoma (PDAC) is constitutively active KRasG12D, which induces neoplastic transformation of acinar cells through acinar-to-ductal metaplasia (ADM). We have previously shown that KRasG12D-induced ADM is dependent on RAC1 and EGF receptor (EGFR) by a not fully clarified mechanism. Using three-dimensional mouse and human acinar tissue cultures and genetically engineered mouse models, we provide evidence that (i) KRasG12D leads to EGFR-dependent sustained fluid-phase endocytosis (FPE) during acinar metaplasia; (ii) variations in plasma membrane tension increase FPE and lead to ADM in vitro independently of EGFR; and (iii) that RAC1 regulates ADM formation partially through actin-dependent regulation of FPE. In addition, mice with a pancreas-specific deletion of the Neural-Wiskott–Aldrich syndrome protein (N-WASP), a regulator of F-actin, have reduced FPE and impaired ADM emphasizing the in vivo relevance of our findings. This work defines a new role of FPE as a tumor initiating mechanism.
机译:液相内吞作用是体内平衡过程,在肿瘤的发生中起未知的作用。胰腺导管腺癌(PDAC)的驱动程序突变是组成型活性KRas G12D ,它通过腺泡到导管化生(ADM)诱导腺泡细胞的肿瘤转化。先前我们已经表明,KRas G12D 诱导的ADM通过尚未完全阐明的机制依赖于RAC1和EGF受体(EGFR)。使用三维小鼠和人类腺泡组织培养物和基因工程小鼠模型,我们提供了证据:(i)KRas G12D 在腺泡化生过程中导致EGFR依赖性持续液相内吞(FPE); (ii)血浆膜张力的变化增加了FPE,并在体外独立于EGFR导致了ADM; (iii)RAC1部分通过肌动蛋白依赖性FPE调节ADM的形成。此外,具有胰腺特异性缺失的神经-维斯柯特-奥尔德里奇综合症蛋白(N-WASP)(F-肌动蛋白的调节剂)的小鼠降低了FPE并损害了ADM,强调了我们发现的体内相关性。这项工作定义了FPE作为肿瘤启动机制的新作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号